Research programme: rabies nanoparticle therapies - NanoViricides
Alternative Names: RabiCide™-ILatest Information Update: 28 Jul 2021
At a glance
- Originator NanoViricides
- Class Antivirals; Polymers
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Rabies
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for preclinical development in Rabies in USA (Parenteral)
- 28 Jul 2021 No recent reports of development identified for preclinical development in Rabies in Vietnam (Parenteral)
- 24 Jul 2019 Rabies nanoparticle therapies is still in preclinical trials for Rabies in USA, Vietnam (NanoViricides pipeline, July 2019)